BG
CSTL icon

Bellevue Group’s Castle Biosciences CSTL Stock Holding History

Bellevue Group’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-301,103
Closed -$6.03M – 146
2025
Q1 		$6.03M Sell
301,103
-444,879
-60% -$11M 0.14% 81
2024
Q4 		$19.9M Sell
745,982
-516,048
-41% -$15.7M 0.38% 62
2024
Q3 		$36M Buy
1,262,030
+44,929
+4% +$1.14M 0.58% 51
2024
Q2 		$26.5M Sell
1,217,101
-2,984
-0.2% -$66.5K 0.43% 61
2024
Q1 		$27M Sell
1,220,085
-12,293
-1% -$267K 0.41% 69
2023
Q4 		$26.6M Buy
1,232,378
+4,347
+0.4% +$76.5K 0.41% 65
2023
Q3 		$20.7M Buy
1,228,031
+103,988
+9% +$1.82M 0.33% 73
2023
Q2 		$15.4M Buy
1,124,043
+175,165
+18% +$3.55M 0.22% 87
2023
Q1 		$21.6M Buy
948,878
+4,566
+0.5% +$112K 0.31% 76
2022
Q4 		$22.2M Buy
944,312
+2,441
+0.3% +$56.6K 0.3% 79
2022
Q3 		$24.6M Buy
941,871
+812
+0.1% +$22.8K 0.35% 75
2022
Q2 		$20.7M Buy
941,059
+333,445
+55% +$7.75M 0.29% 86
2022
Q1 		$27.3M Buy
+607,614
New +$25.1M 0.32% 85

Other funds holding CSTL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return

Bellevue Group's CSTL Position: Q2 2025 in Review

Bellevue Group sold out of Castle Biosciences (CSTL) in Q2 2025, closing a stake of 301,103 shares — an estimated $6.03M sold.

Bellevue Group first reported a position in CSTL in Q1 2022 and held it in 13 quarters. The position peaked at $36M in Q3 2024. 152 funds tracked by Wall St. Rank hold CSTL as of Q2 2025.

  • Bellevue Group reported no remaining Castle Biosciences position as of Q2 2025 after selling out during the quarter.
  • Bellevue Group sold 301,103 Castle Biosciences shares in Q2 2025, an estimated $6.03M.
  • Bellevue Group first reported a position in Castle Biosciences in Q1 2022 and held it in 13 quarters.
  • Bellevue Group's Castle Biosciences position peaked at $36M in Q3 2024.
  • 152 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2025.

Based on Bellevue Group's 13F filing for Q2 2025, filed 14 Aug 2025.